Clinical Trial Update: Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies [Phase 4]

View source ↗

Summary

Phase 4 trial examining the pharmacodynamic effects of low-dose rivaroxaban in combination with antiplatelet therapies; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Coronary Artery Disease
• Peripheral Arterial Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease, Peripheral Arterial Disease | Phase 4 | Status: COMPLETED | Results posted: 2022-06-27